Multiple Opportunities27 Oct 2019 15:05
“NXP002 targets a key mechanistic pathway shared by many forms of fibrosis, meaning effective oral delivery of NXP002 could treat multiple fibrotic diseases.“
Multiple Fibrotic diseases.
We’re speaking with multiple Pharmaceutical Companies.
When a Company patents a drug that has the potential to address multiple diseases be assured that the potential value here is ‘many multiples’ of where we are currently.
And this is just one product in our PF.
The skill of a clever investor is being able to appreciate early on how big that potential is, and remaining ‘on-Board’ to allow the investment to reach its real value.
I’m sensing we have a number of shrewd investors here already, who will still be here as this Company smashes a staggering Valuation.
Good luck all, this story is just starting, & I strongly believe 2020 could be a mesmerising year for Nuformix.
Nuformix, The ASOS of Pharma, you heard it hear first.